Vancomycin

DoseMe Expands Global Footprint as Premier Hospitals and Cancer Centers across Australia Continue to Adopt Bayesian Dosing

Retrieved on: 
Mercredi, avril 17, 2024
Software, Pharmaceutical, Oncology, Health, Infectious Diseases, Hospitals, Health Technology, Technology, Mortality, Austin Hospital, Royal North Shore Hospital, Aminoglycoside, Hospital, Risk, Vancomycin, Safety, Research, Royal Perth Hospital, Attention, Acute kidney injury, HITRUST, Patient, Toxicity, AKI, Medicine, Algorithm, Pharmacist, Growth, Pharmaceutical industry

DoseMe , a leading provider of model-informed precision dosing (MIPD) software, is pleased to announce the continued growth in Australia.

Key Points: 
  • DoseMe , a leading provider of model-informed precision dosing (MIPD) software, is pleased to announce the continued growth in Australia.
  • The precision dosing software has informed over 400,000 dosing decisions, benefiting more than 10,000 patients and gaining the trust of over 1,000 clinicians nationwide.
  • “It is exciting to see the global demand around precision dosing, with Australia continuing to be a trailblazer,” said Paul Edwards, CEO of DoseMe.
  • This surge in clientele was boosted by strategic partnerships worldwide, underscoring DoseMe's commitment to global expansion and continuous innovation to deliver advanced precision dosing.

Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.

Retrieved on: 
Jeudi, avril 11, 2024
Biotechnology, Surgery, Health, Pharmaceutical, Cardiology, FDA, Baxter, USP, Sodium chloride, Injection, Blood pressure, Baxter International, Anesthesia, Patient, Regadenoson, Antimalarial medication, Infection, Hypotension, Catecholamine, Vasopressin, Vancomycin, Pharmaceutical industry

“We are proud to offer important new options for our customers and look forward to continuing to bring new innovations to the market.”

Key Points: 
  • “We are proud to offer important new options for our customers and look forward to continuing to bring new innovations to the market.”
    Product launches within Baxter’s Pharmaceuticals portfolio in the U.S. include the following.
  • For all products, please see full Indications, Important Risk Information and links to full Prescribing Information below.
  • Baxter offers the first and only FDA-approved ready-to-use Norepinephrine in Dextrose, and now provides Norepinephrine in 4 mg/250 mL, 8 mg/250 mL and 16 mg/250 mL strengths.
  • Baxter now offers Vancomycin in 500 mg/100 mL, 750 mg/150 mL, 1 g/200 mL, 1.25 g/250 mL and 1.5 g/300 mL strengths.

OsteoRemedies® Obtains Expanded Indications for SPECTRUM® Dual Antibiotic Bone Cement

Retrieved on: 
Mardi, avril 23, 2024
FDA, Patient, Research, MRSA, Infection, Vancomycin

MEMPHIS, Tenn., April 23, 2024 /PRNewswire/ -- OsteoRemedies® LLC, an orthopedic company focused on providing simple solutions to complex disorders, has announced FDA clearance for expanded indications for the SPECTRUM® GV Bone Cement.

Key Points: 
  • MEMPHIS, Tenn., April 23, 2024 /PRNewswire/ -- OsteoRemedies® LLC, an orthopedic company focused on providing simple solutions to complex disorders, has announced FDA clearance for expanded indications for the SPECTRUM® GV Bone Cement.
  • Initially launched in 2018, SPECTRUM® GV Bone Cement is the first commercially available dual antibiotic bone cement on the US market.
  • Containing both vancomycin and gentamicin, SPECTRUM® GV Bone Cement prevents bacterial adhesion of susceptible organisms, intermediate-resistant, and methicillin-resistant staphylococcal infections.
  • From a mechanical performance perspective, testing of SPECTRUM® GV Bone Cement has been compared to commercially available single antibiotic bone cements and found to have substantially equivalent mechanical integrity.

Media Advisory: DoseMe Bioinformatician and Chief Science and Strategy Officer Co-Author Abstract Big Data Bayesian Truths to Be Covered in Oral Presentation at the 24th ECCMID Annual Meeting

Retrieved on: 
Mardi, avril 9, 2024
Biotechnology, Pharmaceutical, Health, Infectious Diseases, Hospitals, Health Technology, Genetics, Clinical Trials, Congress, Midwestern University, BCPS, Doctor of Pharmacy, Professor, AUC, Patient, Big data, Vancomycin, Safety, ESCMID, ECCMID, European, Infection, Pharmaceutical industry

ECCMID is the annual meeting of ESCMID, the European Society of Clinical Microbiology and Infectious Diseases, a registered non-profit organization in Basel, Switzerland.

Key Points: 
  • ECCMID is the annual meeting of ESCMID, the European Society of Clinical Microbiology and Infectious Diseases, a registered non-profit organization in Basel, Switzerland.
  • Abstract co-authored Dr. Sharmeen Roy, PharmD, BCPS , Chief Strategy and Science Officer and Paul Sabourenkov , Lead Bioinformatician at DoseMe.
  • What: Abstract 05305, Big Data Bayesian Truths: no vancomycin trough concentration target is sufficiently precise for safety or efficacy.
  • Details: Title: Big data Bayesian truths: no vancomycin trough concentration target is sufficiently precise for safety or efficacy.

FDA Approves New Antibiotic for Three Different Uses

Retrieved on: 
Mercredi, avril 3, 2024
Daptomycin, Research, Hypersensitivity, Hypokalemia, Fungal infection, Aztreonam, Dizziness, Pneumonia, Survival, Dysgeusia, Potassium, Seizure, Abdominal pain, Dietary supplement, CABP, Headache, Patient, Public, Insomnia, Bacterial pneumonia, Food and Drug Administration, Animal, Bilirubin, Diarrhea, History, Mortality, Vancomycin, Leukopenia, Clostridioides, Human services, Injection site reaction, Nausea, Rash, Priority review, Bronchopneumonia, Skin, Fever, Heated tobacco product, Ceftriaxone, Safety, SAB, Anemia, Division, Phlebitis, Cosmetics, Vaccine, Infection, Food, Vomiting, Blood, Multimedia, FDA, Periodic breathing, ABSSSI, Pharmaceutical industry

"The FDA will continue our important work in this area as part of our efforts to protect the public health."

Key Points: 
  • "The FDA will continue our important work in this area as part of our efforts to protect the public health."
  • Zevtera's efficacy in treating SAB was evaluated in a randomized, controlled, double-blind, multinational, multicenter trial .
  • In the trial, researchers randomly assigned 390 subjects to receive Zevtera (192 subjects) or daptomycin plus optional aztreonam [the comparator] (198 subjects).
  • A total of 69.8% of subjects who received Zevtera achieved overall success compared to 68.7% of subjects who received the comparator.

New to The Street Airs Episode 556 Featuring Five Corporate Interviews, Broadcast on the FOX Business Network Monday, February 19, 2024, at 10:30 PM PT

Retrieved on: 
Vendredi, février 16, 2024
Carbon, Hospital, Watt, Mining, News, Somnolence, DNX, Bacteria, FINRA, Global X ETFs, Patient, Corporation, BTC, POW, Biopharmaceutical, Television, Carbon footprint, Pain, Wind, CDI, Vancomycin, Fox Business, Ecosystem, SBP, Interview, Miner, Partnership, Woman, Nursing, Sleep, ESG, Insomnia, Business, Decentralization, EnergySolutions, Fibromyalgia, Tonix Pharmaceuticals, MD, Sustainability, FDA, Patent, SBC, Food, Tongue, United States patent law, Medicine, Headache, Publication, Cryptocurrency

New to The Street's Episode 556 line-up features the following five (5) Corporate interviews:

Key Points: 
  • New to The Street's Episode 556 line-up features the following five (5) Corporate interviews:
    2).
  • Tonix's new drug, called Tonmya™, is a new class of medicine that controls pain in those who have fibromyalgia.
  • Fibromyalgia is common in women who have been unsuccessful in finding current marketplace drugs limited in the treatment success.
  • Clinical studies have shown that Tonmya™ can eliminate most pain, enhance sleep, and diminish fatigue in patients.

DoseMe Expands Vancomycin Hemodialysis Model

Retrieved on: 
Jeudi, février 15, 2024
Technology, Health Technology, Software, Biotechnology, Health, Pharmaceutical, General Health, Data Management, Artificial Intelligence, BCPS, TDM, Toxicity, Obesity, HD, Dialysis, Vancomycin, Doctor of Pharmacy, Risk, Medicine, Patient, IHD, Medical device

DoseMe , a leading provider of model informed precision dosing, today announced the availability of its new Vancomycin Hemodialysis (HD) model.

Key Points: 
  • DoseMe , a leading provider of model informed precision dosing, today announced the availability of its new Vancomycin Hemodialysis (HD) model.
  • The vancomycin hemodialysis (HD) model enables personalized dosing that reduces the necessity for multiple blood draws for vancomycin levels.
  • Implementing this optimized model could further enhance precision and personalization of vancomycin therapy in hemodialysis patients.
  • Overall, integrating the optimized model with DoseMeRx has potential to improve vancomycin dosing accuracy and outcomes in the hemodialysis population.

New to The Street Announces its 553rd Episode TV Line Up, Featuring Five Corporate Guests, Airing on the FOX Business Network, Monday, February 5, 2024, 10:30 PM PT

Retrieved on: 
Vendredi, février 2, 2024
Parent, Nursing, Multi, OTCQB, Wind, Bacteria, Foodservice, News, Biopharmaceutical, DNX, COVID, FDA, Host, Name, WNBA, Business development, Privacy, Female, Endeavor Group Holdings, Major League, NFL, Woman, Partnership, Internet, Nord Anglia Education, Big Tech, BPEA EQT, Student, Television presenter, CDI, OTCQX, Virtual reality, IMG, Collection, FRA, Patient, Publication, Marketing, Vancomycin, Blood, Brain, IP, Tune, Cancer, Hospital, Interview, PROMO, MLS, Genetics, Athlete, Street, BPEA, Education, IMG Academy, Major League Soccer, Sport, Online shopping

Specializing in sales/marketing, revenue management solutions, and guest services, property owners and renters have had great experiences when engaging the Company .

Key Points: 
  • Specializing in sales/marketing, revenue management solutions, and guest services, property owners and renters have had great experiences when engaging the Company .
  • With a national footprint, property owners can expand beyond local or regional markets, optimizing rental listings to increase rental opportunities.
  • Heather explains that owners become actual CEOs of their properties, enhanced by a back-office team using technology and providing service support.
  • The Compass Collection can assist an owner looking for a more sophisticated level of infrastructure, which can promote higher revenues and rental bookings.

New to The Street TV Announces Episode #552 with its Five Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, February 1, 2024, at 9:30 PM PT

Retrieved on: 
Jeudi, février 1, 2024
Parent, Travel, Nursing, Multi, OTCQB, Wind, Bacteria, Foodservice, News, Biopharmaceutical, DNX, COVID, FDA, Host, Name, WNBA, Privacy, Female, Decentralization, Endeavor Group Holdings, Major League, NFL, Woman, Partnership, Internet, Coffee, Nord Anglia Education, Big Tech, BPEA EQT, Student, Bloomberg Television, Television presenter, CDI, OTCQX, Virtual reality, Consultant, IMG, FRA, Patient, Publication, Vancomycin, Blood, Brain, IP, Tune, Cancer, Hospital, Interview, PROMO, MLS, Genetics, Athlete, BPEA, Stone Brewing Co., Education, IMG Academy, Major League Soccer, Sport

New to The Street's TV episode #552 will air the following five (5) business interviews:

Key Points: 
  • New to The Street's TV episode #552 will air the following five (5) business interviews:
    1).
  • As a clinical-stage biopharmaceutical business, ACXP is developing a new class of antibiotics for life-threatening bacterial infections.
  • Based on positive data from Phase 2a and Phase 2b, management is now going forward with the FDA Phase 3.
  • The Company compared its top-line data with the currently used standard-of-care drugs in the marketplace, and Ibezapolstat has impressive positive results .

New to The Street Announces Episode 551, Five Corporate Interviews, Airing on the FOX Business Network, Monday, January 29, 2024, at 10:30 PM PT

Retrieved on: 
Vendredi, janvier 26, 2024
Corporation, Wind, Artificial intelligence, Cancer, Big Tech, Host, Carbon, Virtual reality, COP, LTD, Decentralization, Privacy, IP, Television presenter, Food security, Tune, Bacteria, Marketing, Multi, Brain, Blood, Nutrient, Fox Business, Genetics, Nursing, Climate change, Investment, OTCQX, Internet, Blue Castle, Patient, Hospital, Partnership, Name, DNX, Interview, OTCQB, VRM, CDI, Vancomycin, FDA, PROMO, News, Publication, FRA, Cryptocurrency

As a clinical-stage biopharmaceutical business, ACXP is developing a new class of antibiotics for life-threatening bacterial infections.

Key Points: 
  • As a clinical-stage biopharmaceutical business, ACXP is developing a new class of antibiotics for life-threatening bacterial infections.
  • Based on positive data from Phase 2a and Phase 2b, management is now going forward with the FDA Phase 3.
  • The Company compared its top-line data with the currently used standard-of-care drugs in the marketplace, and Ibezapolstat has impressive positive results .
  • Phases 2a and 2b confirmed that the drug had success in 25 out of 26 patients, approximately 94% success with no reinfections.